ImmunoGen Up on Positive Pipeline Data - Analyst Blog


Shutterstock photo

ImmunoGen Inc. 's ( IMGN ) shares have been up over a couple of trading sessions following the company's announcement of encouraging initial results on its oncology candidate, IMGN853, on Apr 8. The stock has gained over 8% since the announcement.

Results from the company's research, which aimed at optimizing the dosing of IMGN853, revealed that clinical activity has been seen with the candidate starting at doses of 3.3 mg/kg.

ImmunoGen stated that dosing of IMGN853 as per adjusted ideal body weight, rather than total body weight, would bring down the variability among patients in the concentration of IMGN853 in their blood. ImmunoGen has changed the dosing of IMGN853 as per adjusted ideal body weight from total body weight in the ongoing phase I study following its research insights.

The company intends to present additional data on the candidate in the coming months. We note that ImmunoGen is currently evaluating IMGN853 in a phase I study for the treatment of folate receptor α (FRα)-positive cancer forms like ovarian, endometrial and lung cancer.

We are encouraged by ImmunoGen's progress with its pipeline so far. Apart from IMGN853, the company also has IMGN529 (non-Hodgkin lymphoma) and IMGN289 (different forms of cancer) in its pipeline. We expect investor focus to remain on ImmunoGen's pipeline.

ImmunoGen presently carries a Zacks Rank #1 (Strong Buy). Some other stocks worth considering include Questcor Pharmaceuticals, Inc. ( QCOR ), Alkermes ( ALKS ) and Mallinckrodt ( MNK ). All the stocks carry a Zacks Rank #1.

ALKERMES INC (ALKS): Free Stock Analysis Report

IMMUNOGEN INC (IMGN): Free Stock Analysis Report

MALLINCKRODT PL (MNK): Free Stock Analysis Report

QUESTCOR PHARMA (QCOR): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
More Headlines for: ALKS , IMGN , MNK , QCOR

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by